Ansgar A. Wegener

This paper introduces a new CRBN construct for efficient binder discovery, showing it outperforms existing constructs in binding and production, and applies it to identify potent CRBN binders from a large compound library.

This paper introduces a platform for creating tumor-targeting antibody-PROTAC conjugates that enhances bioavailability and specificity without modifying PROTACs or antibodies.